Lawrence Snyder, T. Neklesa, Xin Chen, Hanqing Dong, C. Ferraro, D. Gordon, Jennifer Macaluso, J. Pizzano, Jing Wang, Ryan R. Willard, N. Vitale, R. Peck, Marcia Dougan Moore, C. Crews, J. Houston, A. Crew, I. Taylor
{"title":"43 .首次发现雄激素受体降解蛋白PROTAC治疗男性转移性去势抵抗性前列腺癌的ARV-110","authors":"Lawrence Snyder, T. Neklesa, Xin Chen, Hanqing Dong, C. Ferraro, D. Gordon, Jennifer Macaluso, J. Pizzano, Jing Wang, Ryan R. Willard, N. Vitale, R. Peck, Marcia Dougan Moore, C. Crews, J. Houston, A. Crew, I. Taylor","doi":"10.1158/1538-7445.AM2021-43","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":12258,"journal":{"name":"Experimental and Molecular Therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"17","resultStr":"{\"title\":\"Abstract 43: Discovery of ARV-110, a first in class androgen receptor degrading PROTAC for the treatment of men with metastatic castration resistant prostate cancer\",\"authors\":\"Lawrence Snyder, T. Neklesa, Xin Chen, Hanqing Dong, C. Ferraro, D. Gordon, Jennifer Macaluso, J. Pizzano, Jing Wang, Ryan R. Willard, N. Vitale, R. Peck, Marcia Dougan Moore, C. Crews, J. Houston, A. Crew, I. Taylor\",\"doi\":\"10.1158/1538-7445.AM2021-43\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":12258,\"journal\":{\"name\":\"Experimental and Molecular Therapeutics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"17\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Experimental and Molecular Therapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/1538-7445.AM2021-43\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental and Molecular Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/1538-7445.AM2021-43","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Abstract 43: Discovery of ARV-110, a first in class androgen receptor degrading PROTAC for the treatment of men with metastatic castration resistant prostate cancer